SCHEMBL21875342

SCHEMBL21875342

Cc1cc(CO)nc(N2CCCCC2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
GBA1 P04062 1/20 0.45
DNM1L O00429 1/20 0.45
KDM4E B2RXH2 5/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
GAA P10253 3/20 0.42
ACHE P22303 1/20 0.42
ALDH1A1 P00352 5/20 0.41
HPGD P15428 4/20 0.41
HSD17B10 Q99714 3/20 0.41
CYP1A2 P05177 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
LMNA P02545 2/20 0.41
TSHR P16473 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24766048 0.84 KMT2A (0.50) SMN1; SMN2CRHBPCRHR2KDM4EGAA
SCHEMBL20548133 0.83 CRHBP (0.46) SMN1; SMN2CRHBPCRHR2DNM1LKDM4E
SCHEMBL25186884 0.75 HRH3 (0.51) HRH4
SCHEMBL2179648 0.75 GBA1 (0.43) SMN1; SMN2CRHBPCRHR2GBA1CYP1A2
SCHEMBL12250749 0.74 CRHBP (0.59) SMN1; SMN2CRHBPCRHR2GBA1KDM4E
SCHEMBL21875283 0.73 DNM1L (0.71) DNM1L
SCHEMBL12161257 0.73 NOS2 (0.43) ALDH1A1
SCHEMBL18003560 0.73 CASP1 (0.42) SMN1; SMN2CRHBPCRHR2GBA1CYP1A2
SCHEMBL23299953 0.72 KMT2A (0.56) SMN1; SMN2CRHBPCRHR2KDM4EGAA
SCHEMBL24324093 0.72 PDE10A (0.46) SMN1; SMN2CRHBPCRHR2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11168080-B2 Dynamin-1-like protein inhibitors MITOBRIDGE, INC. (US) 2021-11-09 US disclosed
US-11168080-B2 Dynamin-1-like protein inhibitors MITOBRIDGE, INC. (US) 2021-11-09 US disclosed
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-04-30 US disclosed
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS Astellas Engineered Small Molecules US, Incorporated 2020-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11168080-B2 Dynamin-1-like protein inhibitors DNM1L, DNM1, DNM2 SMN1; SMN2 2970/4885CRHBP 845/4885CRHR2 3584/4885
US-20200131172-A1 DYNAMIN-1-LIKE PROTEIN INHIBITORS DNM1L, DNM1, DNM2 SMN1; SMN2 2970/4885CRHBP 845/4885CRHR2 3584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.